What are the recommended treatments for stable chronic obstructive pulmonary disease (COPD) and for acute COPD exacerbations?

Treatment of COPD and COPD Exacerbations

Stable COPD Management

For patients with moderate to severe stable COPD, long-acting muscarinic antagonists (LAMA) are recommended over short-acting agents to prevent exacerbations and improve quality of life. 1

Bronchodilator Therapy

Monotherapy Options:

• LAMA monotherapy is strongly recommended over short-acting muscarinic antagonists for moderate to severe COPD, as it reduces both moderate and severe exacerbations, improves quality of life and lung function, and has fewer serious adverse events 1
• Long-acting beta-agonists (LABA) or LAMA are both effective as initial maintenance therapy 1

Combination Therapy:

• For patients with moderate, severe, or very severe COPD, combination inhaled corticosteroid/LABA (ICS/LABA) is recommended over LABA monotherapy to prevent acute exacerbations, improve health-related quality of life, reduce dyspnea, and improve lung function 1
• The combination ICS/LABA is preferred over ICS monotherapy, which is not recommended for COPD management 1
• LAMA/LABA dual therapy or LAMA monotherapy are both effective options for preventing exacerbations 1
• ICS/LABA combination therapy or LAMA monotherapy are equally effective choices 1

Triple Therapy:

• Triple therapy (LAMA/LABA/ICS) may be considered for patients with stable COPD, though evidence is weaker (Grade 2C) 1
• Continue triple therapy rather than stepping down to dual therapy in patients with moderate to high symptom burden (CAT ≥10) and/or FEV1 <80% predicted 1

Important Caveats:

• ICS-containing regimens increase risk of oral candidiasis, upper respiratory infections, and pneumonia 1
• ICS monotherapy should never be used in COPD 1

Additional Pharmacotherapy

Macrolide Antibiotics:

• For patients with moderate to severe COPD who have ≥1 moderate or severe exacerbation in the previous year despite optimal inhaler therapy, long-term macrolide therapy may be considered to prevent exacerbations 1
• Clinicians must weigh risks of QT prolongation, hearing loss, and bacterial resistance 1

Acute COPD Exacerbation Management

Short-acting inhaled beta-agonists, with or without short-acting anticholinergics, are the initial bronchodilators for treating acute exacerbations. 1

Exacerbation Classification:

• Mild: Treated with short-acting bronchodilators only 1
• Moderate: Requires short-acting bronchodilators plus antibiotics and/or oral corticosteroids 1
• Severe: Requires hospitalization or emergency department visit; may involve acute respiratory failure 1

Pharmacologic Treatment

Systemic Corticosteroids:

• Systemic corticosteroids improve lung function (FEV1), oxygenation, shorten recovery time, and reduce hospitalization duration 1
• Oral corticosteroids are recommended over intravenous in hospitalized patients 1
• Use in both ambulatory and hospitalized patients having exacerbations 1

Antibiotics:

• Antibiotics, when indicated, shorten recovery time and reduce risk of early relapse, treatment failure, and hospitalization duration 1
• Indicated for exacerbations with increased sputum purulence and volume 1
• Recommended for both ambulatory and hospitalized patients with appropriate indications 1

Agents to Avoid:

• Methylxanthines are not recommended due to side effects 1

Respiratory Support

Non-Invasive Ventilation (NIV):

• NIV should be the first mode of ventilation for acute respiratory failure in COPD exacerbations 1
• Strongly recommended for hospitalized patients with acute or acute-on-chronic respiratory failure 1

Post-Exacerbation Management

Critical Interventions:

• Initiate maintenance therapy with long-acting bronchodilators as soon as possible before hospital discharge 1
• Pulmonary rehabilitation should be initiated within 3 weeks after hospital discharge 1
• Pulmonary rehabilitation should NOT be initiated during hospitalization (conditional recommendation against) 1
• Implement appropriate measures for exacerbation prevention immediately after recovery 1

Differential Diagnosis Considerations:

Exacerbations must be differentiated from acute coronary syndrome, worsening congestive heart failure, pulmonary embolism, and pneumonia, as these comorbidities are common in COPD patients 1